Trials / Terminated
TerminatedNCT03367546
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases
Haploidentical Donor T-cell Replete Allogeneic Hematopoietic Cell Transplant Following Reducing Intensity Conditioning for Patients With Selected High Risk Non-Malignant Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 0 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who lack a suitable HLA-matched sibling donor.
Conditions
- Sickle Cell Disease
- Thalassemia
- High Risk Hematologic Disorders
- Cerebral Adrenoleukodystrophy
- Inherited Metabolic Disorders
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood and Marrow Transplant | Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy) |
Timeline
- Start date
- 2018-07-02
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
- First posted
- 2017-12-08
- Last updated
- 2024-07-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03367546. Inclusion in this directory is not an endorsement.